Chronic Graft-versus-host Disease Clinical Trial
Official title:
Analysis of Dendritic Cells in Patients With Acute or Chronic Skin Graft Versus Host Disease
Dendritic cells (DCs) serve as sentries for the immune system. DCs recognize foreign compounds (antigens) in the body, which they internalize and process. When DCs uptake foreign antigens, they migrate to secondary lymphoid organs, where the processed antigens are presented to T cells. Various DC subsets with unique cell lineages, surface protein markers, and tissue localization determinants have been identified. For example, Langerhans cells (LCs) and interstitial dendritic cells (intDCs) are DCs found in stratified epithelia, such as the skin. Though both are expressed in the skin, they differ with respect to their origin and surface protein content and can activate distinct types of immune responses. They may also have different specificities for the capture of antigens and presentation to circulating T cells. To date, it is unknown what role, if any, the different DC populations that reside or repopulate in the skin play in the development and progression of skin graft-versus-host disease (GVHD) following bone marrow transplant.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02991846 -
A Prospective Observational Study for Evaluating CGVHD
|
||
| Recruiting |
NCT02291770 -
Treatment of Chronic Graft-Versus-Host Disease With Mesenchymal Stromal Cells
|
Phase 3 | |
| Terminated |
NCT01226420 -
Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host Disease
|
Phase 2 | |
| Active, not recruiting |
NCT02759731 -
Study of Baricitinib, a JAK1/2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation
|
Phase 1/Phase 2 | |
| Completed |
NCT01862965 -
Treatment of Newly Diagnosed Moderate or Severe Chronic Graft-versus-host Disease With Prednisone and Everolimus
|
Phase 2 | |
| Completed |
NCT02040623 -
Safety and Efficacy Study of R932348 Ophthalmic Solution in Chronic Ocular Graft Versus Host Disease Patients(DROPS-2)
|
Phase 2 | |
| Completed |
NCT02411474 -
Tear Cytokine Analysis as a Prediction or Diagnostic Marker in Ocular GvHD
|
N/A | |
| Active, not recruiting |
NCT01158105 -
Bortezomib for the Treatment of Refractory Chronic Graft-vs-Host Disease(cGVHD)
|
Phase 2 | |
| Terminated |
NCT01903473 -
Donor Regulatory T Cells Infusion in Patients With Chronic Graft-versus-host Disease (GVHD)
|
Phase 2 | |
| Active, not recruiting |
NCT01366092 -
Daily IL-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease
|
Phase 2 | |
| Recruiting |
NCT05690971 -
Psychosocial Mobile App for Chronic Graft-Versus-Host Disease
|
N/A | |
| Recruiting |
NCT02918188 -
Therapeutic Effects of Hydrogen on Steroid-refractory/or Steroid-dependent cGVHD
|
Phase 2 | |
| Recruiting |
NCT01765660 -
Mesenchymal Stem Cells for Treatment of Refractory Chronic Graft-versus-host Disease
|
Phase 2 | |
| Completed |
NCT01956903 -
Treatment of Refractory Acute Graft-Versus-Host Disease by Sequential Infusion of Allogenic Mesenchymal Stem Cell.
|
Phase 1/Phase 2 | |
| Terminated |
NCT03584516 -
GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04692376 -
MSC for Treatment of cGVHD After Allo-HSCT
|
Phase 2 | |
| Completed |
NCT02966301 -
Treatment of Chronic Graft Versus Host Disease With Arsenic Trioxide
|
Phase 2 | |
| Terminated |
NCT01898377 -
Imatinib Mesylate and Mycophenolate Mofetil for Steroid-Refractory Sclerotic/Fibrotic cGVHD in Children
|
Phase 2 | |
| Recruiting |
NCT02669251 -
Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT01161628 -
Rituximab for the Primary Treatment of Denovo Extensive Chronic Graft Versus Host Disease (GVHD)
|
Phase 2 |